Jan 13, 2020 — TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below. 2019 Fourth Quarter and Full-Year Financial Highlights Commercially contracted instruments were 137 in the fourth quarter and 304 […]
Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
Oct 03, 2019 — From IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA) held in Washington, DC October 2 – 6. TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that […]
Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies
Sep 18, 2019 — Accelerate Diagnostics, Inc. recently highlighted the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. “We are thrilled with the results of these clinical studies, which provide further evidence of the clinical value of Pheno,” commented Dr. Romney Humphries, Chief Scientific Officer of […]
Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit
Aug 02, 2019 — Today we announced the release and CE marking of our latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices. The new CE-IVD Accelerate PhenoTest™ BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, and trimethoprim-sulfamethoxazole […]
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
3-6 February, 2020
Dubai World Trade Centre, UAE
Stay up to date with Accelerate by joining our mailing list.Sign up today
16-17 December, 2019
Palais des Congrès de Paris, France
4-6 December, 2019
Hamburg Messe, Germany
11-14 November 2019
9-12 November, 2019
Palacongressi Di Rimini, IT
2-6 October, 2019
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.